Certain tetrahydro-azepinoquinolines of structural formula I are agonists of the mammalian 5-HT2c receptor, and, in particular, are selective agonists of the mammalian 5-HT2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-HT2c receptor, such as obesity, obesity-related conditions, and certain CNS-related disorders, including schizophrenia and depression. They are also useful as aids for tobacco smoking cessation.
结构式 I 的某些四氢氮杂卓
喹啉类化合物是哺乳动物 5-HT2c 受体的激动剂,尤其是哺乳动物 5-HT2c 受体的选择性激动剂。因此,本发明的化合物可用于治疗、控制或预防对 5-HT2c 受体刺激有反应的疾病、病症或紊乱,如肥胖、肥胖相关病症和某些中枢神经系统相关紊乱,包括精神分裂症和抑郁症。它们还可用于戒烟。